| Temporal trends in the treatment of early-and advanced-stage laryngeal cancer in the United States, 1985-2007 AY Chen, S Fedewa, J Zhu Archives of Otolaryngology–Head & Neck Surgery 137 (10), 1017-1024, 2011 | 147 | 2011 |
| Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond J Zhu, AJ Armstrong, TW Friedlander, W Kim, SK Pal, DJ George, T Zhang Journal for immunotherapy of cancer 6, 1-10, 2018 | 144 | 2018 |
| Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities X Lin, W Tang, S Ahmad, J Lu, CC Colby, J Zhu, Q Yu Hearing Research, 2012 | 135 | 2012 |
| Temporal trends in oropharyngeal cancer treatment and survival: 1998–2009 AY Chen, J Zhu, S Fedewa The Laryngoscope 124 (1), 131-138, 2014 | 95 | 2014 |
| Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors JM Conroy, S Pabla, MK Nesline, ST Glenn, A Papanicolau-Sengos, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 93 | 2019 |
| Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients S Pabla, JM Conroy, MK Nesline, ST Glenn, A Papanicolau-Sengos, ... Journal for immunotherapy of cancer 7, 1-13, 2019 | 84 | 2019 |
| Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma MK Labriola, J Zhu, R Gupta, S McCall, J Jackson, EF Kong, JR White, ... Journal for ImmunoTherapy of Cancer 8 (1), 2020 | 81 | 2020 |
| LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types LC Brown, MD Tucker, R Sedhom, EB Schwartz, J Zhu, C Kao, ... Journal for immunotherapy of cancer 9 (3), 2021 | 73 | 2021 |
| Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer MD Tucker, J Zhu, D Marin, RT Gupta, S Gupta, WR Berry, S Ramalingam, ... Cancer medicine 8 (10), 4644-4655, 2019 | 69 | 2019 |
| Immunotherapy is changing first-line treatment of metastatic renal-cell carcinoma MK Labriola, KA Batich, J Zhu, MA McNamara, MR Harrison, ... Clinical genitourinary cancer 17 (3), e513-e521, 2019 | 38 | 2019 |
| Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer T Zhang, J Zhu, DJ George, AJ Armstrong Expert opinion on pharmacotherapy 16 (4), 473-485, 2015 | 36 | 2015 |
| Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer EM Ledet, EF Burgess, AO Sokolova, EB Jaeger, W Hatton, M Moses, ... The Prostate 81 (7), 433-439, 2021 | 31 | 2021 |
| The impact of comorbidity on treatment (chemoradiation and laryngectomy) of advanced, nondistant metastatic laryngeal cancer: a review of 16 849 cases from the national cancer … J Zhu, S Fedewa, AY Chen Archives of Otolaryngology–Head & Neck Surgery 138 (12), 1120-1128, 2012 | 31 | 2012 |
| Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG MP Thorpe, A Kane, J Zhu, MA Morse, T Wong, S Borges-Neto The Journal of Clinical Endocrinology & Metabolism 105 (3), e494-e501, 2020 | 30 | 2020 |
| Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer J Zhu, M Tucker, D Marin, RT Gupta, P Healy, M Humeniuk, C Jarvis, ... Urologic Oncology: Seminars and Original Investigations 37 (11), 813. e1-813. e9, 2019 | 22 | 2019 |
| Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies T Zhang, J Zhu, DJ George, AB Nixon Urologic Oncology: Seminars and Original Investigations 34 (11), 510-518, 2016 | 20 | 2016 |
| Treatment of high-grade metastatic pancreatic neuroendocrine carcinoma with FOLFIRINOX J Zhu, JR Strosberg, E Dropkin, JH Strickler Journal of gastrointestinal cancer 46, 166-169, 2015 | 20 | 2015 |
| Predictors of survival in 211 patients with stage IV pulmonary and gastroenteropancreatic MIBG-positive neuroendocrine tumors treated with 131I-MIBG A Kane, MP Thorpe, MA Morse, BA Howard, JD Oldan, J Zhu, TZ Wong, ... Journal of Nuclear Medicine 59 (11), 1708-1713, 2018 | 18 | 2018 |
| Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients T Zhang, S Pabla, FL Lenzo, JM Conroy, MK Nesline, ST Glenn, ... Oncoimmunology 9 (1), 1773200, 2020 | 16 | 2020 |
| Clinical applications of liquid biopsies in gastrointestinal oncology J Zhu, JH Strickler Journal of gastrointestinal oncology 7 (5), 675, 2016 | 14 | 2016 |
Andrew J. ArmstrongProfessor, Duke UniversityVerified email at duke.edu
